Risankizumab
Interleukin-23 Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: 655066-01, ABBV-066, BI-655066, BI655066, risankizumab (genetical recombination), risankizumab-rzaa, skyrizi
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Risankizumab is a drug in the Interleukin-23 Antagonist class catalogued in DrugCentral. It was first approved by the PMDA in 2019. Its mechanism of action is classified as Interleukin-23 Antagonists. DrugCentral lists 1 molecular target, including IL23A. Recorded indications include Crohn's disease, Erythrodermic psoriasis, Palmoplantar pustulosis and Plaque psoriasis.
- Drug class: Interleukin-23 Antagonist.
- Mechanism of action: Interleukin-23 Antagonists.
- Molecular targets: IL23A (1 listed in DrugCentral).
- Indications: Crohn's disease, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis and Psoriasis and others.
- ATC code: L04AC18 (Interleukin inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (7)
- Crohn's disease
- Erythrodermic psoriasis
- Palmoplantar pustulosis
- Plaque psoriasis
- Psoriasis
- Psoriatic arthritis
- Pustular psoriasis
Mechanism & targets
| Mechanism of action (MoA) | Interleukin-23 Antagonists |
|---|---|
| Established pharmacologic class | Interleukin-23 Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Interleukin-23 subunit alpha | IL23A | inhibitor | Kd 11.00 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-04-26 | EMA | — | AbbVie Deutschland GmbH & Co KG | |
| 2019-04-23 | FDA | — | AbbVie INC | |
| 2019-03-26 | PMDA | — | AbbVie Deutschland GmbH & Co KG |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AC18 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Product storage error | 750.7 |
| COVID-19 | 290.2 |
| Surgery | 265.2 |
| Ileocaecal resection | 253.7 |
| Product temperature excursion issue | 251.7 |
| Death | 242.1 |
| Psoriasis | 235.7 |
| Drug ineffective | 193.3 |
| Intestinal obstruction | 186.4 |
| Therapy interrupted | 181.4 |
| Ileostomy | 169.1 |
| Ileal stenosis | 167.6 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1612838-76-2 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Risankizumab used for?
DrugCentral lists the following indications for Risankizumab: Crohn's disease, Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriasis, Psoriatic arthritis and Pustular psoriasis.
How does Risankizumab work?
Risankizumab is classified as Interleukin-23 Antagonists; its molecular targets in DrugCentral include IL23A (inhibitor).
When was Risankizumab first approved?
Risankizumab was first approved by the PMDA in 2019.
What drug class does Risankizumab belong to?
Risankizumab is in the Interleukin-23 Antagonist class.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5337 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3990029 — compound record and bioactivity
- DrugBank DB14762 — drug record
- FDA UNII 90ZX3Q3FR7 — substance identity
- DailyMed: FDA labels for Risankizumab — current prescribing information (label search)
- UniProt Q9NPF7 (IL23A) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.